Have a feature idea you'd love to see implemented?
Let us know!
NPCE NeuroPace Inc
Price (delayed)
$9
Market cap
$268.63M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.99
Enterprise value
$326.59M
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating
Highlights
NeuroPace's EPS has increased by 34% YoY and by 8% QoQ
NeuroPace's gross profit has increased by 30% YoY and by 6% from the previous quarter
NPCE's equity is down by 40% year-on-year
NeuroPace's quick ratio has decreased by 18% YoY and by 13% QoQ
Key stats
What are the main financial stats of NPCE
Market
Valuations
Earnings
Shares outstanding
29.85M
Market cap
$268.63M
Enterprise value
$326.59M
Price to earnings (P/E)
N/A
Price to book (P/B)
26.75
Price to sales (P/S)
3.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.27
Revenue
$76.45M
EBIT
-$19.25M
EBITDA
-$17.52M
Free cash flow
-$16.79M
Per share
Balance sheet
Liquidity
EPS
-$0.99
Free cash flow per share
-$0.57
Book value per share
$0.34
Revenue per share
$2.6
TBVPS
$3.27
Total assets
$96.3M
Total liabilities
$86.48M
Debt
$73.5M
Equity
$9.82M
Working capital
$67.81M
Debt to equity
7.48
Current ratio
5.59
Quick ratio
4.64
Net debt/EBITDA
-3.31
Margins
Efficiency
Dividend
EBITDA margin
-22.9%
Gross margin
73.8%
Net margin
-36.7%
Operating margin
-30.2%
Return on assets
-28.3%
Return on equity
-205.4%
Return on invested capital
-13.4%
Return on capital employed
-23.6%
Return on sales
-25.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NPCE stock price
How has the NeuroPace stock price performed over time
Intraday
-2.07%
1 week
-7.02%
1 month
45.16%
1 year
4.65%
YTD
-12.71%
QTD
29.12%
Financial performance
How have NeuroPace's revenue and profit performed over time
Revenue
$76.45M
Gross profit
$56.44M
Operating income
-$23.07M
Net income
-$28.09M
Gross margin
73.8%
Net margin
-36.7%
NeuroPace's operating margin has increased by 43% YoY and by 12% from the previous quarter
The net margin has increased by 42% YoY and by 12% from the previous quarter
NeuroPace's gross profit has increased by 30% YoY and by 6% from the previous quarter
The operating income has increased by 28% year-on-year and by 7% since the previous quarter
Growth
What is NeuroPace's growth rate over time
Valuation
What is NeuroPace stock price valuation
P/E
N/A
P/B
26.75
P/S
3.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.27
NeuroPace's EPS has increased by 34% YoY and by 8% QoQ
NPCE's equity is down by 40% year-on-year
The price to book (P/B) is 30% higher than the last 4 quarters average of 20.5
NPCE's revenue is up by 27% year-on-year and by 6% since the previous quarter
NPCE's price to sales (P/S) is 9% less than its last 4 quarters average of 3.8
Efficiency
How efficient is NeuroPace business performance
NeuroPace's return on sales has increased by 49% YoY and by 14% QoQ
NeuroPace's ROE has decreased by 35% YoY and by 5% from the previous quarter
NPCE's ROIC is up by 29% year-on-year and by 8% since the previous quarter
The company's return on assets rose by 21% YoY and by 5% QoQ
Dividends
What is NPCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NPCE.
Financial health
How did NeuroPace financials performed over time
NPCE's total assets is 11% higher than its total liabilities
NeuroPace's quick ratio has decreased by 18% YoY and by 13% QoQ
The company's current ratio fell by 15% YoY and by 12% QoQ
NeuroPace's debt to equity has surged by 71% YoY
NPCE's equity is down by 40% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.